By

phillipsandphillips
Welcome to issue 39 of Multiple Myeloma Research Review. This issue’s selection includes research reporting that switching elderly intermediate-fit patients with MM to reduced-dose lenalidomide maintenance without dexamethasone after nine cycles of Rd was both feasible and provided outcomes similar to those associated with continuing Rd. As usual we have attached the PDF, and now...
Continue Reading
Dear AllWe are now certainly in the grip of a cold winter with many parts of the country experiencing significant snow conditions. I imagine that most of you will have had at least your first vaccination by now. There is some data that shows that myeloma patients are having sub optimal responses to the Pfizer...
Continue Reading
SAVE THE DATE:  Myeloma National Patient Seminar on Saturday 13th November 2021 at the Intercontinental Wellington, 2 Grey Street, Wellington.  9:30am start (9am arrival) to 4pm finish. During this full-day seminar, we will hear from a number of different health professionals on a variety of subjects related to managing myeloma.  We expect this to be...
Continue Reading
This article was originally published on The Limbic Patients with blood cancer – including leukaemia, myeloma, and lymphoma – experience higher psychological distress from risk of COVID-19 infection and unmet needs, finds new research Over a year into the pandemic, we have all felt the effects at this point. But the disruptions and stress haven’t...
Continue Reading
Patients with blood cancer – including leukaemia, myeloma, and lymphoma – experience higher psychological distress from risk of COVID-19 infection and unmet needs, finds new research Over a year into the pandemic, we have all felt the effects at this point. But the disruptions and stress haven’t been spread evenly across the population and the...
Continue Reading
This article was originally posted on The Limbic Addition of isatuximab to carfilzomib–dexamethasone has been hailed “a new standard of care” for patients with relapsed multiple myeloma. The anti-CD38 monoclonal antibody is already approved in combination with pomalidomide and dexamethasone in many countries for relapsed and refractory multiple myeloma. The phase 3 IKEMA trial comparing...
Continue Reading
Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitating a redefinition of SMM and its risk stratification. We assembled a large cohort of SMM patients meeting the revised IMWG criteria to develop a new...
Continue Reading
This Policy Review presents the International Myeloma Working Group’s clinical practice recommendations for the treatment of relapsed and  refractory  multiple  myeloma.  Based  on  the  results  of  phase  2  and  phase  3  trials,  these  recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one  previous  line  of  therapy,  and  for  patients ...
Continue Reading
This article was originally posted on Cure Donna gives advice to other multiple myeloma patients about what she has learned from living with this disease and her various therapies. Cristina Gasparetto, MD: We talked about your quality of life. Sometimes patients, they listen to us as physicians, but they listen to patients more. What type of...
Continue Reading
Australian patients with amyloidosis face a lottery where they may be denied effective medication depending on how strictly their physician interprets the letter of PBS rules, a haematologist has told a parliamentary inquiry. Dr Peter Mollee, head of the Myeloma Service and the Princess Alexandra Hospital Amyloidosis Centre in Brisbane, told the House of Representatives...
Continue Reading
1 2 3 15

Floor 7, 90 The Terrace
Wellington Central
New Zealand